{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-047460","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.559351+00:00","generated_at":"2026-06-14T04:49:09.424749+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Protara Therapeutics annual meeting: all proposals approved by shareholders","bullets":["Class III directors elected: Shefferman 5.68M for, Flannelly 5.63M, Smith 5.66M; 2.26M broker non-votes each.","Ratification of Ernst & Young as auditor passed: 8.16M for, 29,326 against, 709 abstentions.","Advisory vote on named executive officer compensation approved: 5.57M for, 296,338 against, 62,576 abstentions.","Record date April 11, 2023; 11,307,962 shares outstanding and entitled to vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-047460","json":"https://secwatch.observer/filing/0001213900-23-047460.json","markdown":"https://secwatch.observer/filing/0001213900-23-047460.md","text":"https://secwatch.observer/filing/0001213900-23-047460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/ea179944-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:49:09.424749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"044838884127258ffef5662f130127a0f57b972e","claim":"Protara Therapeutics, Inc. shareholders approved Ratification of the selection of Ernst and Young LLP as independent registered public accounting firm at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results were as follows: Votes For Votes Against Abstentions 8,155,867 29,326 709","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"2dc379e61a6a6283e1d7c44769f788cf83cf89d8","claim":"Protara Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,571,777 296,338 62,576 2,255,211","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"5b70fe5692a710b10aabe1398fd1336262dacef8","claim":"Protara Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results were as follows: Votes For Votes Withheld Broker Non-Votes Jesse Shefferman 5,677,709 252,982 2,255,211 Barry Flannelly, Pharm. D. 5,625,929 304,762 2,255,211 Cynthia Smith 5,663,928 266,763 2,255,211","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}